Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Inclusion Criteria:

- Patients chronically infected with hepatitis C virus (HCV) genotype 1 or 4

- HCV RNA viral load of ≥100,000 IU/mL

- No previous exposure to interferon, pegIFNα, or RBV

- Results of a liver biopsy demonstrating absence of cirrhosis obtained ≤24 months
prior to randomization. Compensated cirrhotics with Hepatitis C virus genotype 1
infection are eligible, but will be capped at 10% of the randomized study population
(biopsy can be from any time period prior to randomization)

- Findings on ultrasound, computed tomography scan, or magnetic resonance imaging 12
months prior to randomization that do not demonstrate evidence of hepatocellular
carcinoma

- Body mass index of 18 to 35 kg/m^2

Exclusion Criteria:

- Positive for hepatitis B or HIV-1/HIV-2 antibody at screening

- Evidence of a medical condition associated with chronic liver disease other than HCV

- Evidence of decompensated cirrhosis based on radiologic criteria or biopsy